123 related articles for article (PubMed ID: 14503345)
1. [Radiation recall pneumonitis induced by Gefitinib (Iressa): a case report].
Miya T; Ono Y; Tanaka H; Koshiishi Y; Goya T
Nihon Kokyuki Gakkai Zasshi; 2003 Aug; 41(8):565-8. PubMed ID: 14503345
[TBL] [Abstract][Full Text] [Related]
2. Radiation recall pneumonitis induced by erlotinib after palliative thoracic radiotherapy for lung cancer: Case report and literature review.
Awad R; Nott L
Asia Pac J Clin Oncol; 2016 Mar; 12(1):91-5. PubMed ID: 26846159
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
Argiris A; Mittal N
Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090
[TBL] [Abstract][Full Text] [Related]
4. Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer.
Forsythe B; Faulkner K
Drug Saf; 2004; 27(14):1081-92. PubMed ID: 15554744
[TBL] [Abstract][Full Text] [Related]
5. Acute lung injury as an adverse event of gefitinib.
Inomata S; Takahashi H; Nagata M; Yamada G; Shiratori M; Tanaka H; Satoh M; Saitoh T; Sato T; Abe S
Anticancer Drugs; 2004 Jun; 15(5):461-7. PubMed ID: 15166619
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
7. Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.
Kimura H; Kasahara K; Sekijima M; Tamura T; Nishio K
Lung Cancer; 2005 Dec; 50(3):393-9. PubMed ID: 16153743
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib-induced pneumonitis in non-small cell lung cancer: radiological and clinical findings in five patients.
Park HS; Lee HJ; Im JG; Goo JM; Lee CH; Park CM; Chun EJ
Clin Imaging; 2007; 31(5):306-12. PubMed ID: 17825737
[TBL] [Abstract][Full Text] [Related]
9. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
Tammaro KA; Baldwin PD; Lundberg AS
J Oncol Pharm Pract; 2005 Sep; 11(3):127-30. PubMed ID: 16390601
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
Kris MG; Natale RB; Herbst RS; Lynch TJ; Prager D; Belani CP; Schiller JH; Kelly K; Spiridonidis H; Sandler A; Albain KS; Cella D; Wolf MK; Averbuch SD; Ochs JJ; Kay AC
JAMA; 2003 Oct; 290(16):2149-58. PubMed ID: 14570950
[TBL] [Abstract][Full Text] [Related]
11. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
[TBL] [Abstract][Full Text] [Related]
12. First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.
Kuwako T; Imai H; Masuda T; Miura Y; Seki K; Yoshino R; Kaira K; Utsugi M; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Ishizuka T; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
Cancer Chemother Pharmacol; 2015 Oct; 76(4):761-9. PubMed ID: 26254024
[TBL] [Abstract][Full Text] [Related]
13. [Safety analysis of eight patients treated with erlotinib after severe gefitinib-induced liver injury].
Ohashi Y; Suzuki K; Sakurai M; Ishikawa H; Onishi T; Nakagaki S; Kato T; Shino M; Naito T; Takahashi T; Yamamoto N
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1307-11. PubMed ID: 20647715
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib (IRESSA, ZD 1839) as a salvage treatment for patients with advanced non-small cell lung cancer.
Jubelirer SJ; Yadwadkar KS; Kosowicz AB
W V Med J; 2006; 102(6):14-7. PubMed ID: 17334161
[TBL] [Abstract][Full Text] [Related]
15. [Alveolar hemorrhage as a possible adverse drug reaction by gefitinib (ZD1839, Iressa)].
Ieki R; Saitoh E; Hashimoto E; Ohta T; Yuasa K; Iguchi M; Okamura T; Shibuya M; Moriyama S; Goto H
Gan To Kagaku Ryoho; 2003 Jul; 30(7):977-80. PubMed ID: 12894713
[TBL] [Abstract][Full Text] [Related]
16. The rational basis of using novel targeted biological agents in non-small cell lung cancer.
Ciardiello F
Suppl Tumori; 2002; 1(4):S31-3. PubMed ID: 12415813
[No Abstract] [Full Text] [Related]
17. Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer.
Araki J; Okamoto I; Suto R; Ichikawa Y; Sasaki J
Lung Cancer; 2005 Apr; 48(1):141-4. PubMed ID: 15777982
[TBL] [Abstract][Full Text] [Related]
18. Apparent adverse drug reactions prompt concern about Iressa.
Schultz J
J Natl Cancer Inst; 2003 Apr; 95(8):577-9. PubMed ID: 12697847
[No Abstract] [Full Text] [Related]
19. Radiation recall pneumonitis caused by erlotinib after palliative definitive radiotherapy.
Onal C; Abali H; Koc Z; Kara S
Onkologie; 2012; 35(4):191-4. PubMed ID: 22488089
[TBL] [Abstract][Full Text] [Related]
20. Spared pre-irradiated area in pustular lesions induced by icotinib showing decreased expressions of CD1a+ langerhans cells and FGFR2.
Zhao Q; Wang YN; Wang B
Jpn J Clin Oncol; 2013 Feb; 43(2):200-4. PubMed ID: 23264674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
